Rothschild views Agilent as a leading pure play in life science instruments with diverse end markets (only 34% of revenue from Pharma) and an impressive 64% recurring revenue.

Harding Loevner Portfolio Manager Uday Cheruvu says investors are going to eventually need to see revenue growth to justify high capital expenditures. Cheruvu discusses the latest market movements ...

Hertz (HTZ) may be undervalued, with improved cash flow and reduced leverage risk. Read here for its upside potential as ...

Aeva Technologies, Inc. offers innovative 4D LiDAR sensing technology with strong market potential across various sectors.

The VAT Flat Rate Scheme makes bookkeeping easier by allowing you to pay a fixed percentage of your VAT-inclusive turnover to ...